Clinical trial
A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma
NCT01456039 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma
- Lead sponsor
- Celgene
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 1, 2011
- Completion date
- December 14, 2018
- Enrollment
- 51 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.